Precision medicine for major unmet medical needs
About Us
Changing the way we treat disease
Our approach leverages translational insights and extensive clinical experience to better understand and treat dementia and other disorders. We have a decade of data informing our strategy including patient responder analyses, rigorous dose modeling and flawless clinical execution. As a result, our therapeutic candidates have maximum potential for patient impact.
News & Events
Lighthouse Announces Progression of LHP588 Clinical Development Program in Alzheimer's Disease
Pre-IND meeting related to Phase 2b SPRING trial completed with US FDA. World-class clinical advisory board to support clinical development plans
May 10, 2023 - Lighthouse Pharmaceuticals, a clinical-stage pharmaceutical company developing therapeutics to alter the course of dementia and other degenerative diseases, announced completion of a Pre-investigational New Drug (PIND) meeting with the Food and Drug Administration (FDA) related to the planned Phase 2b clinical study of LHP588 and the formation of its Clinical Advisory Board (CAB). Read more.
Lighthouse Pharma completes acquisition of protease inhibitor portfolio from Quince Therapeutics
Events
March 13, 2023: International Society for CNS Drug Development (ISCDD). Invited presentation: "Heterogeneity in Dementia and Precision Medicine"
May 30, 2023: American Society of Clinical Psychopharmacology (ASCP) Plenary Presentation, Pharmaceutical Pipeline session: "Phase 2 Study Design and New Data from the Phase 1 SAD/MAD Trial of LHP588, a Second-Generation Gingipain Inhibitor for the Treatment of P. Gingivalis-Associated Dementia."
June 13-14, 2023 National Institute on Aging (NIA) : Invited presentation “Biology, mechanisms, oral microbiome and AD” during National Institute on Aging workshop "Oral Health and Alzheimer’s Disease and Related Dementias”
Team
Clinical Advisory Board
